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Abstract: Renal cell carcinoma (RCC) is one of the most lethal genitourinary malignancies. 
Recently, there has been a paradigm shift in the management of advanced RCC. New targeted 
therapies including vascular endothelial growth factor (VEGF) and mammalian target of 
rapamycin (mTOR) inhibitors have been developed which have shown promising results in a 
patient population who otherwise had very few options for treatment. The first mTOR inhibitor, 
temsirolimus, an intravenous prodrug, has shown improved overall survival in poor prognosis 
patients. More recently, an oral mTOR inhibitor, everolimus (RAD 001), has been developed 
which has been shown to delay disease progression in patients with metastatic RCC who have 
progressed on other targeted therapies. Although a survival advantage in phase III trials is 
seen with everolimus, associated systemic toxicities, while generally well tolerated, are not 
insignificant. These include mucositis, hyperglycemia, hyperlipidemia, and pneumonitis. Despite 
the side effects, emerging evidence points to everolimus as the optimal second-line treatment 
for patients with advanced renal cell carcinoma.
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Epidemiology of renal cell carcinoma
Renal cell carcinoma, which accounts for 2% to 3% of all adult malignant neoplasms, 
is the most lethal of all genitourinary malignancies.1 Traditionally, more than 40% 
of patients with RCC have died of their cancer, in contrast with the 20% mortality 
rates associated with prostate and bladder carcinomas.2 Overall, 8.9 new cases are 
diagnosed per 100,000 population per year, with a male-to-female predominance of 
3:2. There is also an age and racial predilection, with typical presentation in the sixth 
and seventh decades of life, and a 10% to 20% higher incidence of RCC in African 
Americans for unknown reasons.3 Approximately 4% of all cases are estimated to 
be familial;3 however, these cases have yielded the most insight into the molecular 
mechanisms of RCC.
With the increasing use of imaging, the incidence of RCC has been increasing by 
an average of 3% per year for whites and 4% per year for African Americans.3 This has 
correlated with an improved 5-year survival rate for patients with small renal masses.4 
Unfortunately, the prognosis associated with advanced RCC (locally advanced, lymph 
node involvement or systemic metastases) remains poor. Lymph node involvement 
has long been recognized as a dire prognostic sign because it is associated with 5- and 
10-year survival rates of 5% to 30% and 0% to 5%, respectively.5 Systemic metastases 
portend a particularly poor prognosis for RCC, with 1-year survival of less than 50%, 
5-year survival of 5% to 30%, and 10-year survival of 0% to 5%.6
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The options for treatment of patients with advanced 
RCC have been limited. Studies have shown that cytokine 
therapy including interferon alpha and interleukin 2 provide a 
moderate response and limited survival benefit.6 Randomized 
data have suggested that cytoreductive nephrectomy 
combined with interferon alpha provides a modest survival 
benefit of 3 months.7 Unfortunately, none of these modalities 
have provided any durable survival advantage for patients 
with advanced RCC. In light of this, new targeted therapies 
have been sought.
Molecular mechanisms of RCC
Several prognostic factors for RCC have been identified 
including pathologic tumor (TNM) stage, tumor size, tumor 
grade and histologic subtype.8 In particular, conventional 
clear cell RCC, which represents 85% of all RCC, has been 
associated with a poor prognosis. The familial form of the 
common clear cell variant of RCC occurs in von Hippel–Lindau 
(VHL) disease. Identification of the VHL (tumor suppressor) 
gene on chromosome 3 has helped elucidate the molecular 
mechanisms of clear cell RCC.
The primary function of the VHL protein complex 
is to target the hypoxia-inducible factor 1 (HIF-1) for 
ubiquitin-mediated degradation, keeping the levels of HIF-1 
low under normal conditions. HIF-1 is an intracellular protein 
that plays an important role in regulating cellular responses 
to hypoxia, starvation, and other stresses. Inactivation or 
mutation of the VHL gene leads to dysregulated expression 
of HIF-1, and this protein begins accumulating within the 
cell.9 This leads to upregulation of the expression of vascular 
endothelial growth factor (VEGF), the primary proangiogenic 
growth factor in clear cell RCC, in addition to platelet derived 
growth factor (PDGF) and glucose transporter (Glut-1), 
which are also involved in tumorogenesis (Figure 1).10
Targeted therapies for RCC
With the identification of VEGF and PDGF in the 
development of clear cell RCC, various therapies targeted 
at inhibiting angiogenesis have been developed. Two 
tyrosine kinase inhibitors (TKI) of the VEGF and other 
pathways, sunitinib and sorafenib, have been shown to 
improve survival in patients with advanced RCC in phase III 
randomized controlled trials. In the first-line management 
of metastatic RCC, sunitinib was found to prolong overall 
survival (OS) (26.4 vs 21.4 months in the placebo group; 
P = 0.05) and progression free survival (PFS) (11 vs 
5.5 months; P  0.001) when compared to interferon alpha 
therapy.11 Sorafenib improved PFS (5.5 vs 2.8 months for 
placebo; P  0.000001) in patients with cytokine refractory 
metastatic RCC.12 These agents have provided a new avenue 
for treatment for patients with advanced RCC. However, 
the tumor may become refractory to these treatments over 
time. As a result, alternative therapies have been sought for 
these patients.
MTOR inhibitors
An additional class of targeted agents known as the 
mammalian target of rapamycin (mTOR) inhibitor has 
become a central target for cancer therapy, RCC in particular. 
The mTOR protein kinase is a 289-kDa serine/threonine 
specific kinase, of which the carboxyl group of TOR is 
similar to the catalytic domain of PI3-kinase (PI3K). mTOR 
primarily functions as a key controller of cell proliferation, 
cell growth, and cell survival.13
mTOR is a central regulator of cell growth and 
proliferation via a mechanism of regulation of translation 
initiation.14 mTOR regulates the translation of ribosomal 
proteins – two proteins in particular: p70S6K1 and 4E-BP1. 
mTOR-dependent phosphorylation of ribosomal p70S6 
kinase causes translation of ribosomal proteins. Translation 
is also regulated by phosphorylation of eukaryotic translation 
initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1). 
Activation of p70S6 kinase and eIF4E by mTOR is induced 
by insulin and other growth factors. Therefore, the mTOR 
pathway controls the translation of mRNA that encode 
proteins that are required for G1 cell-cycle progression and 
S-phase initiation. mTOR acts as a gatekeeper for cell-cycle 
progression, and mTOR inhibition results in prolonged 
G1 phase or G1 arrest.
Currently, two mTOR inhibitors that have been inves-
tigated in phase III trials in the management of metastatic 
RCC: temsirolimus and everolimus.
Temsirolimus
Temsirolimus, or CCI-779, a soluble ester analog of 
rapamycin, was selected for development as an anti-cancer 
agent based on its prominent anti-tumor profile and favor-
able pharmaceutical and toxicological characteristics 
in preclinical studies. Temsirolimus was found to have 
improved aqueous solubility and stability over rapamycin 
as an anti-cancer agent.
A phase III trial in poor-risk advanced RCC patients 
and no prior systemic therapy enrolled 626 patients in an 
open-label study comparing temsirolimus, interferon alpha 
and combination temsirolimus/interferon alpha. Patients 
were randomized in a 1:1:1 fashion to arm 1, interferon Drug, Healthcare and Patient Safety 2010:2 87
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Figure 1 The mammalian target of rapamycin (mTOr) network. mTOr is a central component of the phosphoinositide 3’ kinase/protein kinase B (Pi3K)/Akt signaling pathway 
that mediates eukaryotic cell growth and proliferation. The mTOr kinase is the catalytic component of two distinct multiprotein complexes called mTOr complex 1 (mTOrC1) 
and mTOrC2. mTOrC1 also contains raptor, MLST8, and praline-rich Akt substrate 40 (PrAS40) (a repressor). in tumor cells, mTOrC1 activity is aberrantly elevated. Diverse 
positive and negative growth signals influence the activity level of mTORC1, many of which converge upon the tuberous sclerosis complex 1 (TSC1)/TSC2 complex and Ras 
homolog enriched in brain (rheb). Pi3K receives activating signals from growth factor receptors or it may be activated constitutively in some tumors. Phosphatase and tensin 
homolog (PTeN) reverses the action of Pi3K and functions as a tumor suppressor.   Akt also promotes mTOrC1 activity by phosphorylating TSC1/TSC2 and PrAS40, resulting 
in guanosine-5’-triphosphate (GTP) loading of rheb and suppression of the PrAS40 repressor. Downstream, mTOrC1 phosphorylates the 70-kDa ribosomal protein S6 kinase 
(p70S6K) (activation) and eukaryotic translation initiation factor 4E binding protein (4EBP-1) (inhibition of negative regulator) to increase messenger RNA translation of specific 
proteins. mTOr-regulated proteins include D-type cyclins and c-Myc (which increase cell proliferation), hypoxia-inducible factor-1α (HiF-1α) (which increases synthesis of 
the proangiogenic factor vascular endothelial growth factor [veGF]), various glycolytic enzymes, and growth factors (which can promote cell survival). Activation and inhibi-
tion induced by direct phosphorylation at one or more sites is indicated by a phosphate (P). The mTOr inhibitors (rapamycin, temsirolimus, everolimus, deforolimus) inhibit 
mTORC1 by first binding to the intracellular protein FK506 binding protein 1A, 12 kDa (FKBP12); the resultant mTOR inhibitor-FKBP12 complex then binds mTOR, blocking 
mTORC1 to inhibit its kinase activity.   Through the specific inhibition of mTORC1 activity, the mTOR inhibitors display a multifunctional biologic activity profile, blocking cell 
proliferation, cell growth, cell survival, and angiogenesis in preclinical tumor models.13 Figure reprinted with permission from wyeth Pharmaceuticals, Collegeville, PA, USA.
Abbreviations: MAPK, mitogen-activated protein kinase; S6RP, S6 ribosomal protein.Drug, Healthcare and Patient Safety 2010:2 88
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alpha up to 18 million U subcutaneously 3 times weekly; 
arm 2, temsirolimus 25 mg intravenously once per week; or 
arm 3, temsirolimus 15 mg intravenously once per week + 
interferon alpha 6 million U subcutaneously 3 times weekly.14 
Of these patients, 67% had prior nephrectomy. The primary 
study endpoint was overall survival, and the study was pow-
ered to compare the temsirolimus arms with the interferon 
alpha arm.
Single-agent temsirolimus (n = 209) was shown to 
significantly increase the overall survival (10.9 vs 7.3 months; 
P = 0.0069) of patients with metastatic renal cell carci-
noma and poor risk factors, compared with interferon 
alpha (n = 207). Overall survival by treatment arm was 
7.3 months (interferon alpha), 10.9 months (temsirolimus), 
8.4 months (temsirolimus/interferon alpha). Median PFS 
was 1.9 months (interferon alpha), 3.7 months (temsiroli-
mus), 3.7 months (temsirolimus/interferon alpha). Objective 
response (CR + PR) were 7% (arm 1), 9% (arm 2) and 11% 
(arm 3). The authors concluded that single-agent temsiro-
limus (25 mg intravenously weekly) significantly increases 
the overall survival of first-line, poor-risk advanced renal 
cell carcinoma patients compared with interferon alpha, 
with an acceptable safety profile.
Everolimus
Everolimus (RAD001) is also a derivative of sirolimus and 
has both immunosuppressant and antiangiogenic proper-
ties. It targets the cellular protein mTOR, a regulator of 
signaling pathways associated with the abnormal growth, 
proliferation, and survival of cancer cells.15 Recent evidence 
has added support to the value of everolimus in the treatment 
of metastatic RCC.16
Safety of everolimus  
in advanced RCC
In phase I studies of everolimus in a variety of tumors, 
O’Donnell et al attempted to identify the optimal dosing regi-
men.17 Thirty-seven patients were treated on a weekly regimen 
with dose escalation. Drug limiting toxicity (DLT) occurred 
in 1 of 6 patients at 50 mg but none of 4 patients at 70 mg. 
An additional 37 patients were treated on the daily regimen, 
where DLT occurred in none of 4 patients at 5 mg and in 1 of 
6 patients at 10 mg. Thus, the higher dosage cohorts were 
expanded for each regimen. The maximum tolerated dose 
(MTD) for everolimus was not reached.
The most common drug-related adverse events were 
rash and erythema, which occurred in 44 patients (48%). It 
appeared within the first month in 32 patients, was principally 
acneiform (34%) or erythematous (18%), and occurred most 
commonly over the upper body and head. The frequency of 
occurrence increased with increasing dosage in both the 
daily and weekly treatment groups. Fatigue was observed 
in 31 patients (34%). Grade 3 fatigue was observed in only 
2 patients, in association with stomatitis in 1 patient and 
depression in the other; both patients discontinued therapy. It 
was severe (grade 3) in 1 patient (10 mg/day), with severity 
decreasing to grade 1 after interruption and dose reduction 
to 5 mg/day. Gastrointestinal (GI) toxicities reported in 
61 patients (66%) included stomatitis, nausea, vomiting, 
anorexia, constipation, and abdominal pain or distension. 
Although GI toxicity was usually mild, stomatitis (erythema-
tous, ulcerative) was grade 3 in 3 patients, 1 of whom discon-
tinued treatment. Hematologic abnormalities were reported in 
17 patients. In general, a mostly moderate decrease in platelet 
and neutrophil counts occurred rapidly after introduction 
of treatment but remained constant thereafter. Hemoglobin 
showed a tendency to decline over time, possibly related to 
the underlying disease.
Severe (grade 3 or 4) drug-related adverse events 
occurred in 19 of 92 patients (20.6%), more in the 10 mg 
daily dosing than any other dosing regimen. Five patients 
had severe toxicity that was suspected to be drug related, 
4 of whom required hospitalization. Hemorrhagic gastritis 
occurred after 6 days of therapy (10 mg/day) in an 82-
year-old man with a history of peptic ulcer and without 
thrombocytopenia, who recovered after drug discontinua-
tion. Recurrent epistaxis occurred in a patient (10 mg/day) 
with moderate thrombocytopenia (platelet count, 97 × 
109/L). Bronchiolitis obliterans organizing pneumonia was 
confirmed histologically in 1 patient (70 mg/week) who 
developed cough and dyspnea after 4 to 6 weeks of therapy, 
which worsened to grade 3 severity by month 3 but resolved 
completely after drug discontinuation and glucocorticoid 
therapy. A patient (10 mg/day) with lung metastases and 
grade 2 lymphopenia, without neutropenia, developed grade 
3 pneumonia that resolved with antibiotic therapy. Finally, 
grade 3 fatigue and stomatitis developed in another patient 
after three doses (50 mg/week). There were no suspected 
drug-associated fatalities. The most common severe tox-
icities were mucositis, hyperglycemia and neutropenia 
(3 of 92 for each). Pneumonia represented the only grade 
4 toxicity. Hyperlipidemia (hypercholesterolemia and/or 
hypertriglyceridemia), which was again considered drug 
related, was reported in 7 patients and was grade 3 (hyper-
triglyceridemia) in 2 patients, both of whom improved with 
statin therapy.Drug, Healthcare and Patient Safety 2010:2 89
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Infections were reported in 41 patients. A relationship 
to study drug was suspected in only 12 patients, whose 
infections included cutaneous herpes simplex (5 patients), oral 
candidiasis complicating stomatitis (4 patients), pneumonia 
(2 patients), rhinitis (2 patients), conjunctivitis (1 patient), 
influenza-like illness (1 patient), and a combination of upper 
respiratory and urinary tract infections (1 patient).
Phase II18 and phase III16 trials have found minimal 
adverse drug events in patients with advanced RCC treated 
with everolimus. Common side effects including mouth 
ulcers and stomatitis (36% vs 7% in placebo), asthenia and 
fatigue (28% vs 20%), rash (25% vs 4%), diarrhea (17% vs 
3%), anorexia (16% vs 6%), nausea (15% vs 8%), vomiting 
(12% vs 4%), cough (12% vs 4%), peripheral edema (10% 
vs 3%), pneumonitis (8% vs 0%) and dyspnea (8% vs 2%) 
were seen in both everolimus and placebo groups with 
a low proportion of grade 3 or 4 events for both groups. 
Patients receiving everolimus had higher rates of grade 3 or 
4 stomatitis, infections, and non-infectious pneumonitis than 
did those in the placebo group. Treatment discontinuation 
was required for 28 (10%) patients receiving everolimus 
(with pneumonitis, dyspnea, lung disorder, and fatigue 
the most common reasons) and for 5 (4%) patients in the 
placebo group. Of the 8 patients with grade 3 pneumonitis, 
6 discontinued everolimus therapy. Four showed complete 
clinical resolution, and 3 improved to grade 2 or less. The 
main laboratory abnormalities included anemia, lymphope-
nia, thrombocytopenia and neutropenia. Hypercholesterol-
emia, hypertriglyceridemia, hyperglycemia was higher in 
the everolimus arm.16
Efficacy of everolimus  
in advanced RCC
In phase I studies, partial response (PR) was observed in a 
71-year-old man (70 mg/week) with RCC and in another 
patient with RCC, adrenal and lung lesions had shrunk with 
PR evaluation at 10 mg/day.17 Five of the 10 RCC patients 
remained progression free at 6 months.
A recent phase II trials have looked at the efficacy of 
everolimus in renal cell carcinoma. Amato et al reported 
a median PFS of 11.2 months and the median overall 
survival was 22.1 months in patients with RCC treated 
with everolimus after cytokine or cytotoxic therapy.18 The 
eligibility criteria included predominant clear cell histology, 
measurable disease, adequate organ function, absence of 
central nervous system metastasis, Zubrod performance 
status of 2 or better and no more than 1 prior treatment. The 
therapy was everolimus given at 10 mg daily dose with no 
interruptions on a 28-day cycle. PET-CT was also utilized in 
addition to RECIST defined criteria for response-evaluation, 
which was performed at the end of each cycle for 2 cycles. 
The primary end point was response rate to everolimus 
utilized in the daily dosing schedule of 10 mg orally. Partial 
responses were observed in 5 (14%) patients, stable disease 
lasting at least 3 months was reported in 27 (73%) patients, 
and stable disease lasting at least 6 months was reported in 
21 (57%) patients.
In a randomized, placebo-controlled phase III trial by 
Motzer et al 410 patients were randomized 2:1 comparing 
everolimus to placebo in those patients who had progressed 
on sunitinib or sorafenib or both.16 The primary end-point 
was PFS, with 290 events to achieve 90% power. Secondary 
endpoints were safety, response, patient-reported outcomes, 
and overall survival. Key eligibility criteria were metastatic 
RCC with clear cell component, measurable disease, 
progressive disease on or within 6 months of treatment with 
sunitinib, sorafenib, or both. Exclusion criteria included prior 
exposure to mTOR inhibitors (temsirolimus), untreated brain 
metastasis or uncontrolled co-morbidities. Prior bevacizumab 
and cytokine treatment was permitted.
Of the 410 patients randomized, 272 patients received 
everolimus 10 mg daily, and 138 patients received placebo. 
The median age was 61 years, and 60 years, in the everolimus 
and placebo arms, respectively. The main sites of metastases 
were lung (73%, 81%), bone (37%, 31%) and liver (35%, 
36%). More than 90% of patients in both arms had greater 
than 1 site of metastatic disease. 96% of patients in the 
everolimus arm and 95% of patients in the placebo arm had 
prior nephrectomy. 71% of patients had been treated with 
sunitinib, 55% with sorafenib, and 26% with sunitinib and 
sorafenib. Nearly 71% in the everolimus group and 79% in 
the placebo group had progressed during prior therapy and 
the median length of treatment was 95 days in everolimus 
and 57 days in placebo respectively. Treatment in both 
cohorts continued until progression, severe toxicity, death 
or discontinuation. Randomization was revealed only at 
progression and cross-over to open-label everolimus was 
permissible upon progression on placebo.
Patient discontinuation in the everolimus arm was 31% 
due to progressive disease, 10% due to adverse events, 3% due 
to death. In the placebo arm, 73% patients discontinued due 
to progressive disease, 1% due to adverse events, and 2% 
due to death.
Median PFS was 4.9 months (4 to 5.5 months) for the 
everolimus arm versus 1.9 months (1.8 to 1.9 months) for 
control arm (P  0.0001). The best responses observed Drug, Healthcare and Patient Safety 2010:2 90
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in the two arms were 1% vs 0% partial response, 63% 
vs 32% stable disease, 19% vs 46% progressive disease 
favoring everolimus. In 17% of patients on everolimus and 
22% of patients on placebo, disease could not be assessed. 
At 6 months, progression-free probability was 26% in 
patients receiving everolimus and 2% in patients receiving 
placebo. While there was a significant benefit from evero-
limus, the quality of life data from the original publication 
did not show any difference between everolimus and pla-
cebo. No observable difference was evident between the two 
groups with respect to the time to clear-cut deterioration of 
patient-reported outcomes.
Based on these data showing statistically significant 
improvement in PFS as compared with placebo, everolimus 
established clinical benefit as a second-line therapy in 
patients who progress on first-line targeted therapy, including 
sunitinib and sorafenib. Everolimus can be proposed as the 
new standard of care in the second-line setting for patients 
progressing on targeted therapy with VEGF inhibitor.
While evidence is growing about the role of everolimus as 
a second-line monotherapy for advanced RCC, the combina-
tion of everolimus with another agent is a viable option if the 
second agent targets the signaling in a different pathway.19 
There is recent evidence that the combination of bevacizumab 
(a monoclonal antibody to VEGF) with everolimus in patients 
with advanced RCC (either as first-line therapy or after 
TKI failure) may be associated with a significant objective 
response rate (21%) and stable disease rate/minor response 
rate (69%). Toxicity when these agents are combined 
included proteinuria (19% grade 3–4), fatigue (9% grade 
3–4), mucositis/stomatitis (49% grade 3–4), hyperlipidemia 
(45% grade 3–4), nausea (40% grade 3–4) and hypertension 
(25%).20 The final results of this study are pending; however, 
these preliminary results add weight to the concept of multi 
focal approaches to targeted therapy.
An additional phase I trial combining sunitinib (37.5 mg 
in the 4 weeks on/2 weeks off schedule) and everolimus 
(daily or weekly regimen) reported at the 2009 ASCO Annual 
meeting revealed a significant dose limiting toxicity when 
the two agents were combined.21 The severe adverse events 
included endocarditis, gastrointestinal hemorrhage with 
severe anemia and pulmonary embolism. An altered dosing 
schedule is planned for phase II of this trial.
The role of everolimus  
in advanced RCC
With the emerging evidence for targeted therapies in the 
management of advanced RCC, algorithms have been 
created to help guide best practice for these agents.22 In 
patients with good or intermediate prognosis disease who 
are treatment naive, sunitinib or bevicizimab with interferon 
alpha are suggested treatments; however, for patients with 
poor prognosis, temsirolimus is recommended. Everoli-
mus is best suited for patients with advanced RCC who 
are refractory to tyrosine kinase inhibitors (TKIs) or other 
mTOR inhibitors while sorafenib is recommended for 
patients who are refractory to cytokine therapy.
Conclusions
Based on these data, everolimus is the first agent to show 
clinical benefit in a randomized, double-blind study in patients 
who have progressed on first-line targeted therapy including 
sunitinib and sorafenib, with improvement in overall PFS 
compared to placebo. While everolimus has been associated 
with drug-related toxicity, it appears to be well tolerated in 
phase II and III trials and appears to be quite safe. Trials com-
bining everolimus with other targeted therapies are pending but 
do also appear promising from a tolerability perspective.
Sunitinib remains the first-line treatment for patients with 
advanced RCC. However, the therapeutic benefits of these 
agents become limited over time. As a result, alternative 
treatment options are necessary. Phase III trials of everolimus 
in this patient population have yielded promising results for 
salvage therapy. Thus, everolimus can be proposed as the 
new standard of care in second-line setting for those patients 
progressing on VEGF-inhibitor therapy.
The current frontier of mTOR inhibitors is limited to 
temsirolimus, an intravenous prodrug, and everolimus, an 
orally bioavailable agent. The former is used primarily as 
first-line therapy for poor prognosis patients, whereas everoli-
mus is indicated as second-line therapy for those failing TKIs. 
Clinical trials for everolimus in the first-line setting as well 
as in combination with other targeted therapies are ongoing. 
This agent may yield superior results to TKIs in either pri-
mary monotherapy or in the multimodal therapy setting for 
advanced RCC and provides new hope for the management 
of one the most lethal genitourinary malignancies.
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